Johannes Gleitz

USPTO Granted Patents = 32 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 6)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 73(Granted Patents)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

1 out of 121

Merck Patent Gesellschaft

Years Active: 2005-2013

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8466200 - 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors (2013-06-18),

2. 8431602 - Beta-amino acid derivatives for treatment of diabetes (2013-04-30),

3. 8420642 - Pyridine derivatives useful as glucokinase activators (2013-04-16),

4. 8383838 - 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 (2013-02-26),

5. 8236824 - N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators (2012-08-07),

6. 8232272 - Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same (2012-07-31),

7. 8188288 - 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors (2012-05-29),

8. 8129373 - Carbonyl compounds (2012-03-06),

9. 7951804 - Piperidinyl compounds (2011-05-31),

10. 7906516 - Carbonyl compounds (2011-03-15),

11. 7902223 - Phenyl derivatives as factor XA inhibitors (2011-03-08),

12. 7868172 - 2-(hetero)-aryl substituted tetrahydroquinoline derivatives (2011-01-11),

13. 7763611 - Aroylsemicarbazide derivatives against thromboembolic diseases (2010-07-27),

14. 7732481 - Prolinylarylacetamides (2010-06-08),

15. 7683093 - Prolinyl derivatives for the treatment of thrombosis (2010-03-23),

Title: Innovations and Contributions of Johannes Gleitz in Pharmaceutical Patents

Introduction

Johannes Gleitz, a prominent inventor based in Darmstadt, Germany, has made significant contributions to the field of pharmaceuticals through his innovative research and development. With an impressive portfolio of 32 patents, Gleitz has established himself as a key figure in the creation of compounds that address various health issues, particularly metabolic and neurological disorders.

Latest Patents

Among his recent patent filings, two stand out for their potential impact on healthcare. The first patent focuses on 2-adamantylurea derivatives, which act as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This invention promises to aid in the treatment and prevention of conditions such as metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension, and more.

The second patent introduced novel beta-amino acid derivatives, aimed at the treatment of diabetes. These heterocyclic compounds are designed as activators of glucokinase and hold potential for the prevention and treatment of both Type 1 and Type 2 diabetes, as well as obesity and related complications like neuropathy and nephropathy.

Career Highlights

Throughout his career, Johannes Gleitz has been affiliated with notable companies, including Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His work at these organizations has facilitated the transition of innovative ideas into practical pharmaceutical solutions that can benefit countless individuals worldwide.

Collaborations

Gleitz has collaborated with various professionals in the field, including Christos Tsaklakidis and Dieter Dorsch. These partnerships have not only enriched his research but also expanded the impact of his innovations across different areas of healthcare.

Conclusion

With 32 patents to his name, Johannes Gleitz continues to be a vital contributor to the advancement of pharmaceutical innovations. His groundbreaking work in developing selective inhibitors and novel compounds holds great promise for improving the treatment of numerous health conditions, showcasing his commitment to enhancing human health through inventive solutions.

This text is generated by artificial intelligence and may not be accurate.